EMA Authorised: Humira (adalimumab) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

EMA authorises Humira (adalimumab) for multiple inflammatory diseases across indications, confirming market authorization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Colitis Ulcerosa
• Crohn Disease
• Juvenile Idiopathic Arthritis
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Spondylitis
• Ulcerative Colitis
• Uveitis

Drugs mentioned

• Humira (adalimumab)

Snippet

Status: Authorised. Therapeutic area: Spondylitis, Ankylosing;Arthritis, Juvenile Rheumatoid;Uveitis;Colitis, Ulcerative;Psoriasis;Arthritis, Psoriatic;Crohn Disease;Arthritis, Rheumatoid. MAH: AbbVie Deutschland GmbH & Co. KG. Decision date: 09/07/2026